The TNM classification of breast cancer: Need for change

Curigliano G., Viale G., Bagnardi P.V., Fumagalli L., Locatelli M., Rotmensz N., Ghisini R., Zurrida S., Veronesi P., Goldhirsch A., Clinical Relevance of HER2 Overexpression/amplifica-tion in patients with small tumor size and node-negative breast cancer, J Clin Oncol, 27, pp. 5693-5699, (2009)

Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J., Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system, Journal of Clinical Oncology, 17, 7, pp. 1983-1987, (1999)

Persons D.L., Tubbs R.R., Cooley L.D., Dewald G.W., Dowling P.K., Du E., Mascarello J.T., Rao K.W., Wilson K.S., Wolff D.J., Habegger-Vance G., HER-2 fluorescence in situ hybridization: Results from the survey program of the College of American Pathologists, Arch Pathol Lab Med, 130, pp. 325-331, (2006)

Dal Lago L., Durbecg V., Desmedt C., Salgado R., Verjat T., Lespagnard L., Ma Y., Veys I., Di Leo A., Sotiriou C., Piccart M., Larsimont D., Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer, Molecular Cancer Therapeutics, 5, 10, pp. 2572-2579, (2006)

Perou C.M., Sorlie T., Eisen M.B., Van De Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O.R., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borre-Sen-Dale A.L., Brown P.O., Botstein D., Molecular portraits of human breast tumours, Nature, 406, pp. 747-752, (2000)

Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., Van De Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L., Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications, Proc Natl Acad Sci USA, 98, pp. 10869-10874, (2001)

Curigliano G., Viale G., Bagnardi P.V., Fumagalli L., Locatelli M., Rotmensz N., Ghisini R., Zurrida S., Veronesi P., Goldhirsch A., Clinical Relevance of HER2 Overexpression/amplifica-tion in patients with small tumor size and node-negative breast cancer, J Clin Oncol, 27, pp. 5693-5699, (2009)

Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J., Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system, Journal of Clinical Oncology, 17, 7, pp. 1983-1987, (1999)

Persons D.L., Tubbs R.R., Cooley L.D., Dewald G.W., Dowling P.K., Du E., Mascarello J.T., Rao K.W., Wilson K.S., Wolff D.J., Habegger-Vance G., HER-2 fluorescence in situ hybridization: Results from the survey program of the College of American Pathologists, Arch Pathol Lab Med, 130, pp. 325-331, (2006)

Dal Lago L., Durbecg V., Desmedt C., Salgado R., Verjat T., Lespagnard L., Ma Y., Veys I., Di Leo A., Sotiriou C., Piccart M., Larsimont D., Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer, Molecular Cancer Therapeutics, 5, 10, pp. 2572-2579, (2006)

Perou C.M., Sorlie T., Eisen M.B., Van De Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O.R., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borre-Sen-Dale A.L., Brown P.O., Botstein D., Molecular portraits of human breast tumours, Nature, 406, pp. 747-752, (2000)

Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., Van De Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L., Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications, Proc Natl Acad Sci USA, 98, pp. 10869-10874, (2001)